ArticleBrain & NeuroRehabilitation2026
Transcutaneous Auricular Vagus Nerve Stimulation to Improve Daily-Life Gait in Parkinson's Disease: A Case Report.
Article in Brain & NeuroRehabilitation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transcutaneous auricular vagus nerve stimulation (taVNS) is a promising non-invasive neuromodulation approach for addressing gait impairments in Parkinson's disease (PD). However, evidence regarding its effects on daily-life gait remains limited. We report a case of a 67-year-old woman with PD and freezing of gait (FOG), based on the hypothesis that taVNS may enhance gait automaticity under daily-life conditions. A single-case A-B-C design was used, consisting of baseline, sham stimulation, and taVNS phases. Gait performance was assessed using wearable accelerometry in both experimental and daily-life settings. While no significant changes were observed in gait parameters during experimental assessments, daily-life walking measures-step velocity, step length, variability, and asymmetry-showed improvements during the taVNS phase. Importantly, no falls or FOG episodes were observed during the taVNS phase. These findings support the feasibility of taVNS and provide preliminary support for its potential therapeutic role in enhancing gait automaticity in daily life. Further controlled studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.